JIANG Bin, LIAO Peng-jun. Bortezomib Added to Daunorubicin and Cytarabine during Induction Therapy and to Intermediate-Dose Cytarabine for Consolidation in Patients with Previously Untreated Acute Myeloid Leukemia Age 60 to 75 Years[J]. Journal of Evidence-Based Medicine, 2013, 13(5): 268-270. DOI: 10.3969/j.issn.1671-5144.2013.05.004
|
Citation:
|
JIANG Bin, LIAO Peng-jun. Bortezomib Added to Daunorubicin and Cytarabine during Induction Therapy and to Intermediate-Dose Cytarabine for Consolidation in Patients with Previously Untreated Acute Myeloid Leukemia Age 60 to 75 Years[J]. Journal of Evidence-Based Medicine, 2013, 13(5): 268-270. DOI: 10.3969/j.issn.1671-5144.2013.05.004
|
JIANG Bin, LIAO Peng-jun. Bortezomib Added to Daunorubicin and Cytarabine during Induction Therapy and to Intermediate-Dose Cytarabine for Consolidation in Patients with Previously Untreated Acute Myeloid Leukemia Age 60 to 75 Years[J]. Journal of Evidence-Based Medicine, 2013, 13(5): 268-270. DOI: 10.3969/j.issn.1671-5144.2013.05.004
|
Citation:
|
JIANG Bin, LIAO Peng-jun. Bortezomib Added to Daunorubicin and Cytarabine during Induction Therapy and to Intermediate-Dose Cytarabine for Consolidation in Patients with Previously Untreated Acute Myeloid Leukemia Age 60 to 75 Years[J]. Journal of Evidence-Based Medicine, 2013, 13(5): 268-270. DOI: 10.3969/j.issn.1671-5144.2013.05.004
|
DownLoad: